- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05888207
A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects
A Phase I, Open-label, Fixed-sequence Study to Assess the Effects of Strong CYP1A2 Inhibitor (Fluvoxamine) on Savolitinib Exposure in Healthy Male Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will be a Phase I, open-label, fixed-sequence, 2-treatment period study.
The study will consist of 2 periods. During period 1 of the study, each subject will receive a single oral dose of savolitinib following an overnight fast. A low-fat breakfast will be provided prior to dosing. There will be a minimum washout period of 10 days (14 days between two successive savolitinib doses) between period 1 and period 2.
During period 2 of the study, subject will take oral doses of fluvoxamine alone from Days 1 to 4. There would be no dietary restrictions for fluvoxamine dosing. On Day 5, subjects will take a single oral dose of savolitinib and oral dose of fluvoxamine. On Day 6, subject will receive an oral dose of fluvoxamine alone. Each subject would be involved in the study for 9 weeks (including screening window).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: AstraZeneca Clinical Study Information Center
- Phone Number: 1-877-240-9479
- Email: information.center@astrazeneca.com
Study Locations
-
-
Maryland
-
Brooklyn, Maryland, United States, 21225
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy subjects with suitable veins for cannulation or repeated venipuncture.
- Male subjects must use barrier contraception.
- Have a BMI between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.
- Regular bowel movements.
Exclusion Criteria:
- History of any clinically significant disease or disorder, which in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
- History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
- Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of investigational medicinal product (IMP).
- Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results, vital signs, 12 lead ECG and physical examination.
- QTcF > 450 ms or QT > 500 ms or other ECG abnormality making interpretation more difficult, as judged by the investigator, or a history of additional risk factors for Torsades de Points, which in the opinion of the investigator may put the subject at risk.
- Any positive result on screening for serum hepatitis B surface antigen OR anti-HBc antibody, indicative of active hepatitis B, hepatitis C antibody, or HIV antibody.
- History of latent or chronic infections.
- Known or suspected drug or alcohol abuse or positive drugs of abuse test. History of excessive alcohol assumption or chronic alcohol induced disease. Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.
- Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 1 month (30 days) of Visit 2 (Day -1 of Period 1) or 5 half lives whichever longer in this study or participation in a method development study (no drug) 1 month prior to Visit 2. The period of exclusion begins 1 month after the final dose or 5 half-lives after the final dose or 1 month after the last visit, whichever is the longest.
- History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity.
- Current smokers or those who have smoked or used nicotine products (including e cigarettes) within the 6 months prior to screening.
- Use of any prescribed or non prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies (which include but are not limited to: kava, ephedra [ma hung], ginko biloba, dehydroepiandrosterone, yohimbe, saw palmetto and ginseng), megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer (> 5 half-lives) if the medication has a long half-life.
- Subject has clinical signs and symptoms consistent with COVID-19, or confirmed infection by appropriate laboratory test within the last 4 weeks prior to screening or on admission unless confirmed by a negative SARS CoV-2 PCR test.
- History of severe COVID-19 (hospitalization, extracorporeal membrane oxygenation, mechanically ventilated).
- Excessive intake of caffeine-containing drinks or food.
- Planned in-patient surgery, dental procedure, or hospitalization during the study.
- Receipt of live attenuated vaccine within 30 days prior to the first dose of study drug.
- Received a seasonal flu vaccine (including H1N1, H1N5) 28 days prior to first dose of study drug.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Savolitinib/Savolitinib+Fluvoxamine
In period 1, subjects will receive a single oral dose of savolitinib on Day 1 after overnight fasting.
Following minimum 10 days of washout after the last dose of savolitinib, in period 2 subjects will take oral doses of fluvoxamine alone, twice daily from Days 1 to 4. On Day 5 subject will receive a single oral dose of savolitinib and a twice daily oral dose of fluvoxamine.
On Day 6, subjects will receive a twice daily oral dose of fluvoxamine alone.
|
Savolitinib will be administered as a single oral dose on Day 1 of Period 1 and on Day 5 of Period 2.
Only fluvoxamine will be administered as a twice daily oral dose from Days 1 to 4 of Period 2. On Day 5 of Period 2, subject will receive a twice daily oral dose of fluvoxamine along with savolitinib.
On Day 6 of Period 2, subject will receive a twice daily oral dose of fluvoxamine alone.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum observed plasma (peak) drug concentration (Cmax) for savolitinib
Time Frame: Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
To evaluate the effects of fluvoxamine on savolitinib Cmax in healthy male subjects after administration of a single oral dose.
|
Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
Area under plasma concentration time curve from zero to infinity (AUCinf) for savolitinib
Time Frame: Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
To evaluate the effects of fluvoxamine on savolitinib AUCinf in healthy male subjects after administration of a single oral dose.
|
Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast) for savolitinib
Time Frame: Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
To evaluate the AUClast of savolitinib when administered alone or in combination with fluvoxamine.
|
Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
AUClast for metabolites M2 and M3
Time Frame: Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
To evaluate the AUClast of savolitinib metabolites (M2 and M3) when savolitinib is administered alone or in combination with fluvoxamine.
|
Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
Cmax for metabolites M2 and M3
Time Frame: Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
To evaluate the Cmax of savolitinib metabolites (M2 and M3) when savolitinib is administered alone or in combination with fluvoxamine.
|
Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
AUCinf for metabolites M2 and M3
Time Frame: Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
To evaluate the AUCinf of savolitinib metabolites (M2 and M3) when savolitinib is administered alone or in combination with fluvoxamine.
|
Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
Ratio of metabolite Cmax to parent Cmax (MRCmax)
Time Frame: Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
To evaluate the MRCmax of savolitinib and its metabolites (M2 and M3) when savolitinib is administered alone.
|
Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
Ratio of metabolite AUCinf to parent AUCinf (MRAUCinf)
Time Frame: Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
To evaluate the MRAUCinf of savolitinib and its metabolites (M2 and M3) when savolitinib is administered alone.
|
Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
Ratio of metabolite AUClast to parent AUClast (MRAUClast)
Time Frame: Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
To evaluate the MRAUClast of savolitinib and its metabolites (M2 and M3) when savolitinib is administered alone.
|
Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
Time to reach peak or maximum observed concentration or response following drug administration (tmax) for savolitinib and metabolites (M2 and M3)
Time Frame: Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
To evaluate the tmax of savolitinib and its metabolites (M2 and M3) when savolitinib is administered alone.
|
Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve (t1/2λz) for savolitinib and metabolites (M2 and M3)
Time Frame: Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
To evaluate the t1/2λz of savolitinib and its metabolites (M2 and M3) when savolitinib is administered alone.
|
Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
Terminal rate constant, estimated by log linear least squares regression of the terminal part of the concentration time curve (λz) for savolitinib and metabolites (M2 and M3)
Time Frame: Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
To evaluate the λz of savolitinib and its metabolites (M2 and M3) when savolitinib is administered alone.
|
Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
Number of data points used for λz determination (λzN) for savolitinib and metabolites (M2 and M3)
Time Frame: Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
To evaluate the λzN of savolitinib and its metabolites (M2 and M3) when savolitinib is administered alone.
|
Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
Apparent total body clearance of drug from plasma after extravascular administration (CL/F) for savolitinib
Time Frame: Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
To evaluate the CL/F of savolitinib when savolitinib is administered alone.
|
Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
Volume of distribution (apparent) at steady state following extravascular administration (based on terminal phase) (Vz/F) for savolitinib
Time Frame: Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
To evaluate the Vz/F of savolitinib when savolitinib is administered alone.
|
Period 1: Day 1 to Day 3 and Period 2: Day 5 to Day 7
|
Number of subjects with adverse events (AEs)
Time Frame: From screening (Day -28 to Day -2) to follow up visit (approximately 9 weeks)
|
To assess additional safety and tolerability of savolitnib.
|
From screening (Day -28 to Day -2) to follow up visit (approximately 9 weeks)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Anti-Anxiety Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Selective Serotonin Reuptake Inhibitors
- Fluvoxamine
Other Study ID Numbers
- D5084C00015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal
Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Male Subjects
-
AkesoNot yet recruitingHealthy Male Subjects
-
Sunshine Lake Pharma Co., Ltd.Completed
-
RAPT Therapeutics, Inc.Completed
-
AstraZenecaParexelCompleted
-
Sunshine Lake Pharma Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedHealthy Male SubjectsChina
-
Shanghai Henlius BiotechCompletedHealthy Male SubjectsChina
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
Vigonvita Life SciencesShanghai Institute of Materia Medica, Chinese Academy of SciencesCompleted
Clinical Trials on Savolitinib
-
Hutchison Medipharma LimitedRecruitingNon-small Cell Lung Cancer MetastaticChina
-
Hutchison Medipharma LimitedCompleted
-
AstraZenecaNot yet recruiting
-
Hutchison Medipharma LimitedRecruitingGastric Cancer | Esophagogastric Junction DisorderChina
-
AstraZenecaSCRI Development Innovations, LLCCompletedPapillary Renal Cell CancerUnited States, Canada, United Kingdom, Spain
-
Hutchison Medipharma LimitedActive, not recruitingLung Sarcomatoid CarcinomaChina
-
AstraZenecaQuotient SciencesCompletedCancerUnited Kingdom
-
National Cancer Institute (NCI)TerminatedColorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
AstraZenecaActive, not recruitingNon-Small Cell Lung CancerUnited States, Argentina, India, Taiwan, Thailand, Vietnam
-
Hutchison Medipharma LimitedRecruitingNon-small Cell Lung CancerChina